4-溴-1,3-苯并二恶唑 | 6698-13-1

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 中文名称: 4-溴-1,3-苯并二恶唑
• 中文别名: 4-溴-1,3-苯并二恶茂
• 英文名称: 4-bromo-benzo[1,3]dioxole
• 英文别名: 4-bromobenzo[d][1,3]dioxole；4-bromo-1,3-benzodioxole；2,3-Methylenedioxy-bromobenzene
• CAS: 6698-13-1
• 化学式: C₇H₅BrO₂
• 分子量: 201.019
• InChiKey: VZPMQHSDFWAZHP-UHFFFAOYSA-N

物化性质

• 沸点：
  82 °C
• 密度：
  1.721±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2932999099
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

SDS

Name:	4-Bromo-1 3-benzodioxole 97% Material Safety Data Sheet
Synonym:
CAS:	6698-13-1

Section 1 - Chemical Product MSDS Name:4-Bromo-1 3-benzodioxole 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6698-13-1	4-Bromo-1,3-benzodioxole	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6698-13-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 82 - 83 deg C
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H5BrO2
Molecular Weight: 201.02

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6698-13-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Bromo-1,3-benzodioxole - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 6698-13-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6698-13-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6698-13-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  3-溴邻苯二酚	3-bromo-1,2-dihydroxybenzene	14381-51-2	C6H5BrO2	189.008

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	4-bromo-2,2-dichloro-benzo[1,3]dioxole	——	C7H3BrCl2O2	269.91

反应信息

• 作为反应物：
  描述：

  4-溴-1,3-苯并二恶唑 在 palladium on activated charcoal 盐酸 、 四(三苯基膦)钯 、 氢气 、 三氟乙酸酐 作用下， 反应 12.25h， 生成 5,6-亚甲基二氧基-1-四酮
  参考文献：
  名称：

  Tributylstannyl 4-tributylstannylbut-3-enoate: a useful C-4 homologating agent. Application to the synthesis of aryl iodolactones

  摘要：

  Tributylstannyl 4-tributylstannylbut-3-enoate, readily prepared by radical hydrostannation, is used for the transfer of a but-3-enoic acid synthon. Some of the potentialities of this synthon are established by the synthesis of aryl iodolactones or tetralones (one of them is a key intermediate for ABT-200 synthesis). Copyright (C) 1996 Published by Elsevier Science Ltd

  DOI：

  10.1016/0040-4039(96)01725-x
• 作为产物：
  描述：

  3-溴邻苯二酚 在 sodium hydroxide 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 4-溴-1,3-苯并二恶唑
  参考文献：
  名称：

  Phenyl-substituted sulfonamides

  摘要：

  新型N-[嘧啶-2-基]-和[三嗪-2-基]-氨基甲酰]-1,3-苯并二氧杂环磺胺和1,4-苯并二氧杂环磺胺可作为植物生长调节剂，特别是作为除草剂。

  公开号：

  US04659368A1

文献信息

• Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase
  作者：Andreas Lingel、Martin Sendzik、Ying Huang、Michael D. Shultz、John Cantwell、Michael P. Dillon、Xingnian Fu、John Fuller、Tobias Gabriel、Justin Gu、Xiangqing Jiang、Ling Li、Fang Liang、Maureen McKenna、Wei Qi、Weijun Rao、Xijun Sheng、Wei Shu、James Sutton、Benjamin Taft、Long Wang、Jue Zeng、Hailong Zhang、Maya Zhang、Kehao Zhao、Mika Lindvall、Dirksen E. Bussiere

  DOI：10.1021/acs.jmedchem.6b01473

  日期：2017.1.12

  Inhibiting this activity by small molecules targeting EZH2 was shown to result in antitumor efficacy. Here, we describe the optimization of a chemical series representing a new class of PRC2 inhibitors which acts allosterically via the trimethyllysine pocket of the noncatalytic EED subunit. Deconstruction of a larger and complex screening hit to a simple fragment-sized molecule followed by structure-guided

  PRC2是一种多亚基甲基转移酶，参与早期胚胎发育和细胞生长的表观遗传调控。催化亚基EZH2主要使组蛋白H3的赖氨酸27甲基化，从而导致染色质紧实和肿瘤抑制基因的抑制。通过靶向EZH2的小分子抑制该活性可显示出抗肿瘤功效。在这里，我们描述了代表一类新的PRC2抑制剂的化学系列的优化，该类PRC2抑制剂通过非催化EED亚基的三甲基赖氨酸口袋发生变构作用。解构较大且复杂的筛选物会产生简单的片段大小的分子，然后进行结构引导的再生长和仔细的性质调节，以产生在功能测定和细胞活性中实现亚微摩尔抑制的化合物。
• Substituted Sulfonamide Compounds
  申请人：OBERBOERSCH Stefan

  公开号：US20080249128A1

  公开（公告）日：2008-10-09

  Substituted sulfonamide compounds with bradykinin receptor (B1R) modulating activity; processes for the preparation thereof, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or inhibit pain and/or other disorders and/or disease states.

  用具有激肽酶受体（B1R）调节活性的磺胺化合物替代；制备这些化合物的方法，包括这些化合物的药物组合物，以及使用这些化合物治疗或抑制疼痛和/或其他疾病状态的方法。
• 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle
  申请人：Sekiguchi Yoshinori

  公开号：US20080318923A1

  公开（公告）日：2008-12-25

  It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.

  旨在提供一种对与精氨酸加压素V1b受体相关的病理状况具有疗效的药物。更具体地说，旨在提供一种对抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、消化系统疾病、药物成瘾、癫痫、脑梗死、脑缺血、脑水肿、头部损伤、炎症、免疫疾病、脱发等具有治疗或预防作用的药物。经过深入研究，发现了一种新颖的1,3-二氢-2H-吲哚-2-酮化合物和与杂芳环融合的吡咯烷-2-酮化合物，它们是高度选择性的精氨酸加压素V1b受体拮抗剂，具有高代谢稳定性，表现出有利的血脑屏障穿透和高血浆浓度，从而实现了上述目标。
• FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF
  申请人：GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD.

  公开号：US20180208604A1

  公开（公告）日：2018-07-26

  Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.

  揭示的区域融合环嘧啶化合物，以及中间体、制备方法、组合物及其用途。融合环嘧啶化合物是如下式I所示的化合物，其为互变异构体、对映异构体、顺反异构体、药学上可接受的盐、代谢物、代谢前体或其前药，上述化合物用于制备用于预防、缓解或治疗免疫系统疾病、自身免疫疾病、细胞增殖性疾病、过敏性疾病和心血管疾病中的一种或多种的药物，且该化合物对Janues激酶、FGFR激酶、FLT3激酶和Src家族激酶具有强烈的抑制作用。
• Anti-cancer agents and uses thereof
  申请人：Kelly Martha

  公开号：US20060270686A1

  公开（公告）日：2006-11-30

  The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A 1 is N or CR 1 ; A 3 is N or CR 3 ; A 5 is N or CR 5 ; R 1 , R 3 —R 6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, non-small cell lung and colon.

  本发明涉及新化合物及其盐，它们的合成以及它们作为抗癌剂的用途。这些化合物包括式I的化合物： 和其溶剂化物、水合物和药用可接受盐，其中A 1 为N或CR 1 ；A 3 为N或CR 3 ；A 5 为N或CR 5 ；R 1 ，R 3 —R 6 和L在说明书中有定义；n为0或1；X为在环部分具有6-10个碳的可选择取代芳基，在环部分具有1-3个氮原子的可选择取代的6元杂芳基，在环部分具有0-4个氮原子且可选择具有1个硫原子或1个氧原子的可选择取代的5元杂芳基，或者在其中6元环与5元环或6元环融合的可选择取代的杂芳基，其中在每种情况下1、2、3或4个环原子是从氮、氧和硫中独立选择的杂原子。它们对广泛范围的癌症，特别是白血病、非小细胞肺癌和结肠癌有效。